Literature DB >> 24768295

A new human IgG avidity test, using mixtures of recombinant antigens (rROP1, rSAG2, rGRA6), for the diagnosis of difficult-to-identify phases of toxoplasmosis.

Dorota Drapała1, Lucyna Holec-Gąsior2, Józef Kur1, Bartłomiej Ferra1, Elżbieta Hiszczyńska-Sawicka3, Dariusz Lautenbach4.   

Abstract

The preliminary diagnostic utility of two mixtures of Toxoplasma gondii recombinant antigens (rROP1+rSAG2 and rROP1+rGRA6) in IgG ELISA and IgG avidity test has been evaluated. A total of 173 serum samples from patients with toxoplasmosis and seronegative people were examined. The sensitivity of IgG ELISA for rROP1+rSAG2 and rROP1+rGRA6 was 91.1% and 76.7%, respectively, while the reactivity for sera from patients where acute toxoplasmosis was suspected was higher, at 100% and 95.4%, respectively, than for people with chronic infection, at 88.2% and 70.6%. In this study a different trend in avidity maturation of IgG antibodies for two mixtures of proteins in comparison with native antigen was observed. The results suggest that a new IgG avidity test using the mixtures of recombinant antigens may be useful for the diagnosis of difficult-to-identify phases of toxoplasmosis. For this reason, selected mixtures after the additional tests on groups of sera with well-defined dates of infection could be used as a better alternative to the native antigens of the parasite in the serodiagnosis of human T. gondii infection.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GRA6; IgG avidity; ROP1; Recombinant antigens; SAG2; Toxoplasmosis

Mesh:

Substances:

Year:  2014        PMID: 24768295     DOI: 10.1016/j.diagmicrobio.2014.03.005

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  7 in total

1.  Interpretation of the Elecsys Toxo IgG avidity results for very low and very high index: study on 741 sera with a determined date of toxoplasmosis.

Authors:  H Fricker-Hidalgo; C L'Ollivier; C Bosson; S Imbert; S Bailly; C Dard; R Piarroux; L Paris; H Pelloux
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-12-19       Impact factor: 3.267

2.  Help in the Choice of Automated or Semiautomated Immunoassays for Serological Diagnosis of Toxoplasmosis: Evaluation of Nine Immunoassays by the French National Reference Center for Toxoplasmosis.

Authors:  O Villard; B Cimon; C L'Ollivier; H Fricker-Hidalgo; N Godineau; S Houze; L Paris; H Pelloux; I Villena; E Candolfi
Journal:  J Clin Microbiol       Date:  2016-10-12       Impact factor: 5.948

3.  Identification, production and assessment of two Toxoplasma gondii recombinant proteins for use in a Toxoplasma IgG avidity assay.

Authors:  Ai Ying Teh; Atefeh Amerizadeh; Sabariah Osman; Muhammad Hafiznur Yunus; Rahmah Noordin
Journal:  Pathog Glob Health       Date:  2016-10-04       Impact factor: 2.894

Review 4.  Advances in serological, imaging techniques and molecular diagnosis of Toxoplasma gondii infection.

Authors:  Ali Rostami; Panagiotis Karanis; Shirzad Fallahi
Journal:  Infection       Date:  2018-01-12       Impact factor: 3.553

Review 5.  IgG Avidity Test as a Tool for Discrimination between Recent and Distant Toxoplasma gondii Infection-Current Status of Studies.

Authors:  Lucyna Holec-Gąsior; Karolina Sołowińska
Journal:  Antibodies (Basel)       Date:  2022-08-15

6.  Assessment of an In-House Enzyme-Linked Immunosorbent Assay and IgG Avidity Test Based on SAG1 and GRA7 Proteins for Discriminating between Acute and Chronic Toxoplasmosis in Humans.

Authors:  Aref Teimouri; Mohammad Javad Abbaszadeh Afshar; Sina Mohtasebi; Sanaz Jafarpour Azami; Rasoul Alimi; Hossein Keshavarz
Journal:  J Clin Microbiol       Date:  2021-07-19       Impact factor: 5.948

7.  Toxoplasma gondii Recombinant antigen AMA1: Diagnostic Utility of Protein Fragments for the Detection of IgG and IgM Antibodies.

Authors:  Bartłomiej Ferra; Lucyna Holec-Gąsior; Justyna Gatkowska; Bożena Dziadek; Katarzyna Dzitko
Journal:  Pathogens       Date:  2020-01-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.